ARCT · NASDAQ · Biotechnology

Arcturus Therapeutics (ARCT)

Develops mRNA medicines for rare diseases and a CSL-partnered COVID-19 vaccine.

$13.76
vs last close−0.62 (−4.29%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue432533463921292517313
Cost of revenue000000003010
Gross profit432533463921292514303
634363675054463630343029
Research & development513754593944353023242118
13131512131211101014911
Selling & marketing0000000000−10
General & administrative13131512131211101014911
Other expenses−2−6−5−4−3−20−4−3−400
Operating income−19−18−30−21−11−33−17−12−17−31−30−26
474443323232
Interest income474483333222
Interest expense000000000000
Other non-operating income0−7−4−4−4−3−3−2−3−10−3−2
Income before tax−15−11−26−17−7−30−14−9−13−29−27−24
Income tax expense100000000000
Net income from continuing operations−16−12−27−17−7−30−14−9−13−29−27−24
Net income−16−12−27−17−7−30−14−9−13−29−27−24
EPS, basic−$0.61−$0.32−$1.00−$0.64−$0.26−$1.11−$0.52−$0.34−$0.49−$1.05−$0.95−$0.84
EPS, diluted−$0.61−$0.32−$1.00−$0.64−$0.26−$1.11−$0.52−$0.34−$0.49−$1.05−$0.95−$0.84
Weighted average shares, basic272727272727272727272828
Weighted average shares, diluted272727272727272727272828
EBITDA−18−11−26−16−6−29−13−8−13−20−26−24
Depreciation & amortization111111111110
EBIT−19−11−26−17−7−30−14−9−13−21−27−24